Somnomed Limited (AU:SOM)
ASX:SOM
Top Page
Somnomed Limited
(Sydney:SOM)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$0.67
▲(2.46% Upside)
Action:ReiteratedDate:11/07/25
Somnomed Limited's overall stock score is primarily influenced by its strong revenue growth and effective cash flow management, which are positive indicators. However, significant challenges in profitability and a bearish technical outlook weigh heavily on the score. The negative P/E ratio and lack of dividend yield further impact the valuation negatively.
Positive Factors
Sustained Revenue Growth
Somnomed's consistent revenue growth (~18% reported) indicates durable market adoption of its oral appliance therapy. Over 2–6 months this trend supports expanding clinician uptake and scale economics, enabling reinvestment in distribution and product development to deepen market position.
Negative Factors
Persistent Unprofitability
Despite revenue and gross margin strength, recurring net losses indicate operating expenses outpace core profitability. This structural shortfall limits retained earnings, pressures long-term cash needs if growth continues, and delays realization of shareholder returns until operating leverage is achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Somnomed's consistent revenue growth (~18% reported) indicates durable market adoption of its oral appliance therapy. Over 2–6 months this trend supports expanding clinician uptake and scale economics, enabling reinvestment in distribution and product development to deepen market position.
Read all positive factors
Somnomed Limited (SOM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$141.31M
Dividend YieldN/A
Average Volume (3M)705.41K
Price to Earnings (P/E)52.9
Beta (1Y)1.48
Revenue Growth21.65%
EPS Growth81.40%
CountryAU
Employees300
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.99Price Target Upside52.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Somnomed Limited Business Overview & Revenue Model
Company Description
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obs...
How the Company Makes Money
SomnoMed makes money by selling its oral sleep apnea/snoring devices and related services through a clinician-led channel. The primary revenue stream is the manufacture and sale of custom-fitted oral appliances that are prescribed by sleep physici...
Somnomed Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
58
Neutral
Cash Flow
70
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 118.50M | 111.49M | 91.65M | 83.62M | 72.58M | 62.71M |
| Gross Profit | 68.02M | 66.73M | 55.13M | 45.77M | 39.15M | 33.90M |
| EBITDA | 4.18M | 1.58M | -2.33M | 698.39K | 524.53K | 3.57M |
| Net Income | -2.56M | -3.46M | -12.24M | -8.00M | -4.44M | -1.19M |
Balance Sheet | ||||||
| Total Assets | 79.90M | 80.97M | 69.80M | 62.49M | 58.09M | 56.17M |
| Cash, Cash Equivalents and Short-Term Investments | 18.03M | 17.29M | 16.18M | 11.96M | 15.64M | 21.11M |
| Total Debt | 14.01M | 8.03M | 6.72M | 23.51M | 12.01M | 8.91M |
| Total Liabilities | 29.86M | 34.58M | 24.78M | 40.09M | 30.31M | 24.01M |
| Stockholders Equity | 50.04M | 46.39M | 45.02M | 22.40M | 27.79M | 32.16M |
Cash Flow | ||||||
| Free Cash Flow | 3.71M | 5.36M | -7.72M | -10.29M | -6.93M | -1.43M |
| Operating Cash Flow | 7.85M | 7.78M | -6.33M | -3.88M | 1.86M | 2.71M |
| Investing Cash Flow | -5.98M | -3.98M | -5.34M | -6.41M | -8.47M | -4.37M |
| Financing Cash Flow | -1.56M | -3.38M | 16.68M | 6.61M | 2.09M | -6.80M |
Somnomed Limited Technical Analysis
Negative
0.65
Price Trends
0.67
Negative
0.72
Negative
0.73
Negative
Market Momentum
-0.01
Positive
46.56
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SOM, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.67, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 46.56 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:SOM.
Somnomed Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$141.31M | 52.88 | -5.31% | ― | 21.65% | 81.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$3.61B | -3.16 | -890.76% | ― | 55.91% | 22.60% | |
45 Neutral | AU$30.58M | -1.41 | -165.13% | ― | 23.31% | -17.35% | |
44 Neutral | AU$90.60M | -6.27 | -54.48% | ― | 34.20% | -23.90% | |
44 Neutral | AU$144.05M | -10.00 | -70.29% | ― | ― | -257.32% | |
42 Neutral | AU$55.93M | 62.66 | 0.48% | ― | 2.23% | -263.16% |
* Healthcare Sector Average
AU:SOM
Somnomed Limited
0.65
0.06
9.32%
AU:CMP
Compumedics Limited
0.28
-0.05
-16.42%
AU:IPD
Impedimed Limited
0.02
-0.03
-64.29%
AU:CYC
Cyclopharm Limited
0.75
-0.41
-35.34%
AU:EMV
EMvision Medical Devices Ltd.
1.55
-0.49
-24.02%
AU:4DX
4DMedical Ltd
6.28
5.99
2065.52%
Somnomed Limited Corporate Events
SomnoMed Issues 160,000 Unquoted Options Under Employee Incentive Plan
Mar 20, 2026
SomnoMed Limited has notified the Australian Securities Exchange of the issue of 160,000 unquoted options under its employee incentive scheme. The options, carrying no exercise price and expiring on December 1, 2031, were issued on March 20, 2026 ...
SomnoMed Applies to List 160,000 New Ordinary Shares on ASX
Mar 18, 2026
SomnoMed Limited, an ASX-listed healthcare company focused on sleep-related medical solutions, continues to build its presence in the medical technology market with products aimed at patients and clinicians managing sleep disorders.The company has...
SomnoMed Seeks ASX Quotation for 480,000 New Ordinary Shares
Mar 9, 2026
SomnoMed Limited has applied to the ASX for quotation of 480,000 new ordinary fully paid shares, with an issue date of March 9, 2026. The application indicates these additional securities stem from the exercise or conversion of existing options or...
SomnoMed Options Lapse, Trimming Future Equity Overhang
Mar 9, 2026
SomnoMed Limited has notified the market of the cessation of 171,000 SOMAA options, which were due to expire on 24 June 2027 with an exercise price of $2.00. The options have lapsed because the conditions attached to these rights were not met or h...
SomnoMed posts record half-year revenue and boosts manufacturing capacity
Feb 26, 2026
SomnoMed reported record first-half FY26 revenue of $60.7 million, up 13% year on year, driven by double-digit growth in Europe and North America and stable margins at 61.3%. EBITDA rose 35% to $7.8 million as the company leveraged operating effic...
SomnoMed Seeks ASX Quotation for 260,000 New Ordinary Shares
Jan 13, 2026
SomnoMed Limited has applied for quotation on the ASX of 260,000 new fully paid ordinary shares, to be issued on 13 January 2026. The additional securities arise from the exercise or conversion of existing options or other convertible instruments,...
SomnoMed Options Lapse, Trimming Potential Future Capital Dilution
Dec 31, 2025
SomnoMed Limited has notified the market that 346,000 SOMAA options, which were due to expire on 24 June 2027 with an exercise price of $2.00, have lapsed as the conditions attached to these conditional rights were not satisfied. The cessation of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.